Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    gog-0258
Show Display Options
Rank Status Study
1 Active, not recruiting Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer
Interventions: Drug: Cisplatin;   Radiation: Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: Quality-of-Life Assessment

Indicates status has not been verified in more than two years